builderall

CONFERENCE INFORMATION

Conference Description

The Master Lecture Series (MLS): Advancing Precision Oncology Across Tumor Types is a multidisciplinary, CE activity designed to deliver cutting-edge insights into the application of systemic therapies in cancer care. It will explore the latest clinical data and emerging strategies involving immunotherapies, targeted therapies, antibody-drug conjugates, radioligand therapies, and PARP inhibitors across a range of solid tumors, including gastrointestinal (GI), genitourinary (GU), lung, and breast cancers.

Expert faculty will guide participants through interactive lectures, real-world case discussions, and tumor board-style panels that highlight personalized therapeutic approaches, biomarker-driven treatment decisions, and investigational strategies shaping the future of oncology. Attendees will engage in collaborative learning with a focus on clinical implementation, patient safety, and shared decision-making to improve cancer care outcomes.

This activity is designed to enhance interprofessional collaboration, improve clinical competence, and support evidence-based practices across the oncology care continuum.

Target Audience

This activity is intended for a broad oncology care team, including, physicians (Medical Oncologists, Radiation Oncologists, Surgical Oncologists, and other specialists involved in cancer care), nurses and nurse practitioners, pharmacists, particularly those involved in oncology treatment planning and management, physician associates, residents, fellows, and other healthcare professionals involved in the treatment of patients with cancer. The educational content is tailored to support both academic and community-based oncology providers.

Learner Objectives

At the conclusion of this activity, participants will be better able to:

  • Analyze current and emerging clinical data on systemic therapies, including immunotherapies, targeted agents, antibody-drug conjugates, radioligand therapies, and PARP inhibitors across GI, GU, lung, and breast cancers.

  • Apply biomarker-driven and molecular diagnostic testing (e.g., HER2, RET, KRAS, BRAF, PI3K/Akt) to inform treatment selection and personalize therapy.

  • Evaluate the safety profiles, mechanisms of action, and efficacy outcomes of novel agents to support informed clinical decision-making and patient counseling.

  • Integrate evidence-based strategies for managing toxicities and optimizing sequencing of systemic therapies within multidisciplinary care frameworks.

  • Engage patients in shared decision-making by communicating current standards of care and the role of clinical trials in expanding treatment options.

  • Collaborate across the oncology care team to develop individualized treatment plans that consider tumor characteristics, patient preferences, and emerging research.